申请人:CENTRAX INTERNATIONAL, INC.
公开号:US10640533B2
公开(公告)日:2020-05-05
The present disclosure relates to novel compounds and pharmaceutical compositions thereof which are useful as inhibitors of proteasomes. The compounds provided herein have improved proteasome potency and selectivity, and increased aqueous solubility, and are useful in treating various conditions or diseases associated with proteasomes.
本公开涉及可用作蛋白酶体抑制剂的新型化合物及其药物组合物。本文所提供的化合物具有更好的蛋白酶体效力和选择性,以及更高的水溶性,可用于治疗与蛋白酶体相关的各种病症或疾病。